Cargando…

The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of (89)Zr-DFO-Pertuzumab

Rationale: The overwhelming majority of radioimmunoconjugates are produced via random conjugation methods predicated on attaching bifunctional chelators to the lysines of antibodies. However, this approach inevitably produces poorly defined and heterogeneous immunoconjugates because antibodies have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vivier, Delphine, Fung, Kimberly, Rodriguez, Cindy, Adumeau, Pierre, Ulaner, Gary A., Lewis, Jason S., Sharma, Sai Kiran, Zeglis, Brian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993239/ https://www.ncbi.nlm.nih.gov/pubmed/32042334 http://dx.doi.org/10.7150/thno.39089

Ejemplares similares

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

Therapeutic Response Monitoring with (89)Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
por: Kang, Minwoo, et al.
Publicado: (2022)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
por: Chomet, Marion, et al.
Publicado: (2020)

(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans
por: Adumeau, Pierre, et al.
Publicado: (2016)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Click-to-Release: Cleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
por: Vlastara, Maria, et al.
Publicado: (2023)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

(89)Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas
por: Herrero Alvarez, Natalia, et al.
Publicado: (2023)

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET
por: Vugts, Danielle J., et al.
Publicado: (2016)

Biodistribution PET/CT Study of Hemoglobin-DFO-(89)Zr Complex in Healthy and Lung Tumor-Bearing Mice
por: Kiraga, Łukasz, et al.
Publicado: (2020)

Feasibility of real-time in vivo (89)Zr-DFO-labeled CAR T-cell trafficking using PET imaging
por: Lee, Suk Hyun, et al.
Publicado: (2020)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of (89)Zr Immune-PET Tracers
por: Imura, Ryota, et al.
Publicado: (2021)

Biodistribution of (89)Zr-DFO-labeled avian pathogenic Escherichia coli outer membrane vesicles by PET imaging in chickens
por: Li, Zhe, et al.
Publicado: (2022)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
por: Stergiou, N., et al.
Publicado: (2023)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [(89)Zr]Zr-DFO-PEG(5)-Tz
por: Lumen, Dave, et al.
Publicado: (2022)

Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using ((89)Zr)-DFO- Galectin3-F(ab')(2) mAb
por: Varasteh, Zohreh, et al.
Publicado: (2021)

Mesenchymal Stem Cells Do Not Lose Direct Labels Including Iron Oxide Nanoparticles and DFO-(89)Zr Chelates through Secretion of Extracellular Vesicles
por: Gao, Yue, et al.
Publicado: (2021)

Evaluation of (89)Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET
por: Radaram, Bhasker, et al.
Publicado: (2023)

Preclinical PET imaging with the novel human antibody (89)Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues
por: Kelly, Marcus P, et al.
Publicado: (2021)

Site-specifically labeled (89)Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model
por: Kristensen, Lotte K., et al.
Publicado: (2019)

Immunoglobulin-binding Sites of Human FcαRI (CD89) and Bovine Fcγ2R Are Located in their Membrane-distal Extracellular Domains
por: Craig Morton, H., et al.
Publicado: (1999)

Improved image reconstruction of (89)Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm
por: Kirchner, Julian, et al.
Publicado: (2021)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

Structural insights into the interaction of human IgG1 with FcγRI: no direct role of glycans in binding
por: Oganesyan, Vaheh, et al.
Publicado: (2015)

Cyclic versus Noncyclic Chelating Scaffold for (89)Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
por: Summer, Dominik, et al.
Publicado: (2017)

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

[(89)Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models
por: Lu, Yun, et al.
Publicado: (2021)

An Interaction Library for the FcεRI Signaling Network
por: Chylek, Lily A., et al.
Publicado: (2014)

The beta subunit of the Fc epsilon RI is associated with the Fc gamma RIII on mast cells
Publicado: (1992)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lkl9nogg3anme6shggjcpu9nq